On December 18, 2019 Diagnostics firm Shuwen reported it entered into collaboration with ASK Pharma to develop a companion diagnostics (CDx) for novel targets in the oncology space (Press release, Shuwen Biotech, DEC 18, 2019, View Source [SID1234552455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The diagnostics will support ASK’s various novel clinical candidates, which aims to introduce highly innovative and efficacious drugs to the domestic Chinese and international markets. The collaboration will leverage Shuwen’s mature immunohistochemistry (IHC) companion diagnostic platform and is expected to produce a number of market novel diagnostic solutions to hospitals and healthcare providers in the coming years. The collaboration also includes the use of Shuwen’s CAP-accredited central lab to test patient samples from ASK’s clinical trials from clinical sites across China.